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hel lenic- journal -of -cardiology/EditorialStroke risk stratification in hypertrophic cardiomyopathyHypertrophic cardiomyopathy (HCM), a common inherited car-
diac disease, is defined by the presence of left ventricular (LV) wall
thickness which is not solely explained by abnormal loading condi-
tions.1 The prevalence of HCM is 1 in 500 in most studies, but using
combined clinical parameters and genetic carriers, HCM could
affect 1 in 200.2 Patients with HCM have excess mortality compared
with general population,3 the pooled 5- and 10-year survival rate of
HCM is 82.2% and 75%, respectively.4 Sudden cardiac death, heart
failure and stroke are the major mortality risks with thromboem-
bolic events occurring in 1 to 4 per 100 person-years.5-11
Population-based cohorts observed progressively increased inci-
dence of stroke among HCM patients following their diagnosis.12,13
Prompt risk stratification for thromboembolism is thereby of great
importance.
Atrial fibrillation (AF) is the most common cardiac arrhythmia in
HCM, affecting 20-25% of patients with HCM,with incidence of 2.5%
new cases annually.6,13-16 In patients with HCM, AF is associated
with the pooled 7-fold increase in thromboembolism, 3-fold in-
crease in heart failure, 2.5-fold increased risk of mortality as
compared to HCM patients with sinus rhythm in a recent system-
atic review.16 Given the high risk of thromboembolism in patients
with HCM, the European Society of Cardiology (ESC) guideline rec-
ommended anticoagulation for all HCM patients with co-existing
AF, irrespective of their CHA2DS2-VASc score.1,17 Indeed, HCM re-
flects substrate abnormalities when evaluating the patient with
AF, and invariably is associated with heart failure with preserved
ejection fraction (HFpEF).18
Oral anticoagulation (OAC) is associated with markedly reduced
pooled incidence of total thromboembolism in patients with HCM
compared with the use of antiplatelet therapy or no treatment
(9.5% vs 22.1%). Among OACs, the direct oral anticoagulants
(DOAC) outperformed Vitamin K antagonists (VKA) in the associa-
tion with lower thromboembolic event (4.7% vs 8.7%), major
bleeding event (3.8% vs 6.8%), and all-cause mortality (4.1% vs
16.1%) among patients with HCM.19
Various risk factors such as presence of AF, left atrial (LA) size,
age, and CHA2DS2-VASc score have been identified based on
different cohort studies on HCM (see Table 1). Both CHADS2 and
CHA2DS2-VASc scores have been applied in cohorts of HCM.8,11 In
a population-based cohort of 17,371 patients with HCM with
absence of AF at baseline, CHA2DS2-VASc score 0-2 was associated
with 1.5-2 fold increase in ischaemic stroke compared with general
population with AF, whereas no significant difference was noted in
stroke rate between HCM patients with CHA2DS2-VASc score3 as
compared with control.12 Other risk scores have been proposed,
one incorporated the CHADS2 score, left ventricular outflow tractPeer review under responsibility of Hellenic Society of Cardiology.
https://doi.org/10.1016/j.hjc.2020.11.003
1109-9666/© 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V. Thi
org/licenses/by-nc-nd/4.0/).gradient (LVOTG), and presence of permanent AF,7 while the HCM
Risk-CVA score included parameters such as age, presence of AF,
interaction between age and AF, prior thromboembolism, the
New York Heart Association Functional classification (NYHA) II or
III/IV, LA diameter, vascular disease, maximal wall thickness
(MWT) and the square of MWT.8 The HCM Risk-CVA score has
been validated in a cohort of 417 patients with HCM, results
showing limited value for clinical utility10 (see Table 1).
In this issue of Hellenic Journal of Cardiology, Wang et al. pre-
sented their study which validated the R-CHA2DS2-VASc score in
a cohort of 446 patients with HCM.20 The CHA2DS2-VASc score
(congestive heart failure, hypertension, age 75 (doubled), dia-
betes, stroke (doubled), vascular disease, age 65e74, and female
sex) is most commonly used in the risk stratification for stroke in
AF,21 although the female sex (Sc) criterion is a risk modifier rather
than a risk factor.22 The R-CHA2DS2-VASc score was previously pro-
posed for stroke risk estimation in patients with myocardial infarc-
tion, which included additional components such as renal function
including blood urea nitrogen (BUN) and estimated glomerular
filtration rate (eGFR), performance of a revascularization procedure,
and presence of AF on the basis of CHA2DS2-VASc score.23
In this study byWang et al,20 a moderate discriminative value in
thromboembolism was demonstrated with C-statistic 0.77 (95%
confidence interval: 0.65-0.89) using the R-CHA2DS2-VASc score.
This significant improvement in risk stratification for thromboem-
bolism as compared to previous cohorts using CHA2DS2-VASc
score8,12 is most likely due to the addition of AF into the risk
scheme, rather than the letter “R” (renal function). Whereas HCM
has been recognized as an independent risk factor for end-stage
renal disease,24 there is no evidence supporting reduced renal func-
tion as an independent risk factor for thromboembolism in patients
with HCM. Also, many of the determinants of renal impairment are
represented by the components of CHA2DS2-VASc, eg. age, hyper-
tension, diabetes, vascular disease etc. Furthermore, in this study,
eGFR 30-59% (16.5% of the cohort) was risk factor for thromboem-
bolism on univariate analysis (only 2.9% of the cohort had
eGFR<30%), and BUN was not a risk factor for thromboembolism.
Hence, kidney disease is unlikely to have contributed significantly
to the discriminative power of the clinical risk score. Additionally,
only 2.5% of the cohort had revascularization to add the additional
component in the R-CHA2DS2-VASc score.
Clinical risk stratification is an evolving field, and much focus
has been directed to improve clinical risk prediction. Given the lim-
itations of clinical risk scores, the aim of clinical risk stratification
for thromboembolism has shifted to initially identify the true
low-risk patients, which is perhaps especially relevant in HCM.
The high-risk group of HCM patients with AF is already advised
to be offered anticoagulation and HCM patients at the verys is an open access article under the CC BY-NC-ND license (http://creativecommons.
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rate in HCM with score2y
Similar stroke rate with
score3y
HCM Risk-CVA score: consists of age, AF, interaction between age and AF, prior TE, NYHA II or III/IV, LA diameter, vascular disease, MWT, MWT2.
CI: confidence interval, HR: hazard ratio, LA: Left atrial size, LVOTG: left ventricular outflow tract gradient, MWT: Maximal wall thickness, NYHA: New York Heart Association
Functional classification, TE: thromboembolic event.
* Significant association with thromboembolic event in multivariate analysis.
y compared with matched general population with AF.
J. Zhang, T. Potpara and G.YH. Lip Hellenic Journal of Cardiology 61 (2020) 318e320minimum should score 1 point on the C criterion (due to HFpEF) us-
ing the CHA2DS2-VASc score, as defined for AF.
Increasingly complex clinical risk scores may improve predic-
tion at least statistically, but this needs to be balanced against
simplicity and practicality for used in busy everyday clinical set-
tings. Addition of biomarkers (whether urine, blood or imaging
ones) will always improve on clinical risk prediction, again statisti-
cally but the clinical difference is marginal, especially in real world
clinical practice.25 Many biomarkers are non-specific, being predic-
tive of outcomes beyond those of interest.26,27 Indeed, statistical
significance is not the same as clinical significance.
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